Search results
Results From The WOW.Com Content Network
Ceftriaxone, sold under the brand name Rocephin, is a third-generation cephalosporin antibiotic used for the treatment of a number of bacterial infections. [4] These include middle ear infections, endocarditis, meningitis, pneumonia, bone and joint infections, intra-abdominal infections, skin infections, urinary tract infections, gonorrhea, and pelvic inflammatory disease. [4]
Since August 2012, the third-generation cephalosporin, ceftriaxone, is the only recommended treatment for gonorrhea in the United States (in addition to azithromycin or doxycycline for concurrent Chlamydia treatment). Cefixime is no longer recommended as a first-line treatment due to evidence of decreasing susceptibility. [30] Ceftriaxone ...
Distribution: It has been reported that after cefuroxime axetil administration, it can be found in tonsil tissue, sinus tissue, bronchial tissue and middle ear effusion. [ 5 ] Elimination: After cefuroxime production, the body is unable to metabolize the drug, and is eliminated unchanged in the urine.
These infections include otitis media, strep throat, pneumonia, urinary tract infections, gonorrhea, and Lyme disease. [5] For gonorrhea typically only one dose is required. [6] In the United States it is a second-line treatment to ceftriaxone for gonorrhea. [5] It is taken by mouth. [5] Common side effects include diarrhea, abdominal pain, and ...
Chronic sinus infections, snoring. On top of having sinus infections that would not subside, Agler, now 34, also “started to snore out of nowhere,” in 2017. Doctors wondered if he had sleep apnea.
Odontogenic sinusitis is a type of sinusitis (inflammation of the sinuses), specifically caused by dental infections or procedures. [1] Comprising approximately 10-12% of all chronic sinusitis cases, this condition primarily affects the maxillary sinus , which is in close proximity to the upper teeth .
Because sinusitis typically is preceded by an infection of the nasal mucosa, some authors suggest generally replacing the term “sinusitis” with “rhinosinusitis”. [1] The functional unity of the two mucosa speaks in favor of this replacement. A distinction is made between acute and chronic rhinosinusitis.
It also finds use as oral continuation therapy when intravenous cephalosporins (such as ceftriaxone) are no longer necessary for continued treatment. Cefpodoxime inhibits peptidoglycan synthesis in bacterial cell walls. It has an oral bioavailability of approximately 50%, which is increased when taken with food. It has an elimination half-life ...